Tetanus Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-aged adults by van der Heiden, Marieke et al.
  
 University of Groningen
Tetanus Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-
aged adults






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van der Heiden, M., Duizendstra, A., Berbers, G. A. M., Boots, A. M. H., & Buisman, A-M. (2017). Tetanus
Toxoid carrier protein induced T-helper cell responses upon vaccination of middle-aged adults. Vaccine,
35(42), 5581-5588. https://doi.org/10.1016/j.vaccine.2017.08.056
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Vaccine 35 (2017) 5581–5588Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineTetanus Toxoid carrier protein induced T-helper cell responses upon
vaccination of middle-aged adultshttp://dx.doi.org/10.1016/j.vaccine.2017.08.056
0264-410X/ 2017 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding authors at: RIVM, Centre for Infectious Disease Control,
Postbaknummer 41, Postbus 1, 3720 BA Bilthoven, The Netherlands.
E-mail addresses: marieke.van.der.heiden@rivm.nl (M. van der Heiden),
annemarie.buisman@rivm.nl (A.-M. Buisman).Marieke van der Heiden a,b,⇑, Aafke Duizendstra a, Guy A.M. Berbers a, Annemieke M.H. Boots b,
Anne-Marie Buisman a,⇑
aCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
bDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
a r t i c l e i n f oArticle history:
Received 31 January 2017
Received in revised form 15 August 2017
Accepted 27 August 2017








MenACWY-TTa b s t r a c t
Introduction: Vaccines frequently induce suboptimal immune responses in the elderly, due to immuno-
logical ageing. Timely vaccination may be a strategy to overcome this problem, which classifies middle-
aged adults as an interesting target group for future vaccine interventions. However, the immunological
fitness of the middle-aged population is ill-defined. It is currently unknown whether effective T-cell help
towards B-cells is initiated by conjugate-carrier vaccines at middle-age.
Aim: We characterized systemic Tetanus Toxoid (TT) specific T-helper cell responses in the circulation of
middle-aged adults (50–65 years of age, n = 31) having received the MenACWY-TT vaccination.
Methods: Blood samples were taken pre- as well as 7 days, 28 days, and 1 year post-vaccination. TT-
specific T-cell responses were determined by IFNc Elispot and by the secretion of IFNc, IL13, IL10,
IL17, and IL21 in cell culture supernatants. Circulating CD4+CXCR5+ICOS+IL21+ cells were analyzed by
flow cytometry, and meningococcal and TT-specific IgG responses by bead-based immunoassays. The cor-
relation between the T-cell help and humoral responses was evaluated.
Results: Vaccination with a TT-carrier protein induced a mixed TT-specific Th1 (IFNc), Th2 (IL13, IL10),
and Th17 (IL17) response in most participants. Additionally, circulating CD4+CXCR5+ICOS+IL21+ cells
were significantly increased 7 days post-vaccination. Pre-vaccination TT-specific cytokine production
and post-vaccination Th2 responses correlated positively with the increase of CD4+CXCR5+ICOS+IL21+
cells. No correlation between T-cell help and antibody responses was found.
Conclusion: The characteristics of the T-cell response upon a TT-carrier vaccination suggests effective T-
cell help towards B-cells in response to meningococcal polysaccharides, although the absence of a corre-
lation with the antibody responses warrants further clarification. However, the robust T-helper cell
response in middle-aged adults, decades after previous TT vaccinations, strengthens the classification
of this age group for future vaccine interventions in the context of population ageing.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Immunological ageing is characterized by clear compositional
changes in the T-cell compartment [1–5], which become already
apparent in the 6th decade of life [2]. This immunological ageing
increases the susceptibility towards infectious diseases and
reduces the immune response to vaccines [6]. Therefore, timely
vaccination is essential to circumvent the impact of this so called
‘immunosenescence’ and thereby enhance memory immunity inthe ageing population. Consequently, future vaccination programs
need to be developed towards a life-course scheme [7–9]. From
this perspective middle-aged adults are an interesting group for
studying appropriate future vaccine programs. However, informa-
tion about the immunological fitness and consequently vaccine
responses in middle-aged individuals is lacking.
It is currently unknown whether conjugate-carrier vaccines are
able to induce effective T-helper cell responses in middle-aged
adults. In infants, carrier proteins are used to induce T-cell help
to the B-cell epitopes in order to generate long-term protection
and memory B-cell formation in response to bacterial polysaccha-
rides [10]. Not only the strength but also the type of the T-helper
cell response influences the quality of the T-cell help. In general
Th2 responses provide more efficient B-cell help than do Th1
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response [11–14]. In addition, T-cell help is mainly provided by fol-
licular helper T-cells (TFH-cells) within the germinal centers (GCs),
where the B- and T-cells interact [15,16]. With advancing age,
altered numbers of these TFH-cells, lower TFH-cell functionality,
and diminished formation of GCs were observed [17,18], possibly
negatively affecting the T-cell help after conjugate-carrier vaccina-
tion in older age groups.
Interestingly, it was recently described that an ongoing B:T-cell
interaction in the GCs is mirrored by higher frequencies of TFH-cells
in the circulation at 6 to 8 days post-vaccination [15,18–21]. Until
now, no consensus on the exact phenotype of circulating TFH-cells
is established. Similar to GC TFH-cells, circulating CXCR5+ cells
were previously described to promote B-cell differentiation and
antibody secretion [13,22–24]. A key characteristic of TFH-cells is
the production of interleukin 21 (IL21), a cytokine involved in GC
development, Ig isotype switching, hyper-mutation of the IgG
heavy chain, IgG affinity maturation, and memory B-cell formation
[13,25–28]. Moreover, the inducible costimulatory molecule (ICOS)
was found essential in the interaction of TFH-cells with the follicu-
lar B-cells [17,29,30]. Finally, multiple studies described roles for
programmed cell death 1 (PD1) in phenotype characterization of
the peripheral TFH-cells [13,15,18,20,22,31]. Although some studies
suggest a direct link between the TFH-cell and the humoral
responses [18,20,32], this is currently unclear.
In this study, we determined the induced T-cell responses initi-
ated by a TT-carrier protein in the circulation of middle-aged
adults (50–65 years of age) having received the TT-conjugated
MenACWY vaccine (Nimenrix), in order to evaluate the T-cell help
provided to B-cells in response to the bacterial polysaccharides in
this age group. This information is essential for the understanding
of T-helper cell responses at older ages and adds to knowledge on
the immunological fitness of middle-aged adults.2. Materials and methods
2.1. Study subjects and blood sampling
Thirty-one relatively healthy middle-aged (50–65 years of age)
participants were randomly selected from a larger cohort. All par-
ticipants were intramuscularly vaccinated with one dose of the TT-
conjugated MenACWY vaccine (Nimenrix, GlaxoSmithKline (GSK)).
Potential participants were excluded based on the following crite-
ria: antibiotic use of fever (>38 C) within the last 14 days, serious
diseases demanding immune suppressive medical treatment
within the last 3 months, a known or suspected immune defi-
ciency, a blood coagulation disorder, a neurologic disorder, admin-
istration of blood products in the past 6 months, serious surgery
within the last 3 months, the use of hormone supplementation,
pregnancy, a suspected allergy towards the vaccine components,
history of serious adverse events after previous vaccinations, a pre-
vious meningococcal vaccination, a previous meningococcal epi-
sode, a tetanus vaccination within the last 5 years, and any
vaccination in the month before enrolment. Additional health char-
acteristics of these participants are presented in Supplementary
Table 1.
The Medical Ethical Committee: Medical Research Ethics Com-
mittees United (mec-U) (NTR4636) approved the study and writ-
ten informed consent was obtained from all participants prior to
the study. All procedures were in accordance with the Declaration
of Helsinki.
Blood samples were taken pre-, as well as 7 days, 28 days, and
1 year post-vaccination. Peripheral blood mononuclear cells
(PBMCs) were isolated using Vacutainer cell preparation tubes
(CPT) containing sodium citrate (Becton Dickinson (BD)), accordingto the manufacturer’s prescriptions. Cells were washed with RPMI-
1640 medium (Gibco) supplemented with 1% heat inactivated fetal
calf serum (FCS, Gibco), 1% Penicillin and Streptomycin (Lonza).
PBMCs were counted and 7.5 ⁄ 106 cells/mL were frozen in a 90%
FCS 10% DMSO solution at 135 C until further use. Serum was
collected using serum clotting tubes (BD) and was stored at 20
until use.
From the initial cohort, PBMC samples obtained in sufficient
quantities at all 4 time points were available from 31 participants
for analysis. TT-specific T-cell responses were determined in 22
participants, whereas TFH-cell markers were investigated in 20 par-
ticipants. Samples from 11 participants provided enough cells for
analysis in all assays (Fig. 1).
2.2. Tetanus specific T-cell stimulation and IFNc Elispot
PBMC stimulation, supernatant collection and the IFNc Elispot
method were consecutively performed as previously described
[33]. Based on prior titration and kinetics experiments, 3 ⁄ 105
PBMCs/well were stimulated for 5 days with medium containing
5% AB serum (Sigma Aldrich) only (negative control), or with addi-
tion of 6.67 Lf/mL purified tetanus toxoid (NVI Bilthoven, The
Netherlands) or 5 lg/mL Pokeweed mitogen (Sigma) as a positive
control, in triplicate. Thereafter, stimulated cells were transferred
to anti-IFNc-coated Elispot plates (Mabtech) for 18 h. Elispot plates
were scanned with the Epson ELISPOT Scanner and spots enumer-
ated with the AELVIS software, using a standardized protocol. Anti-
gen specific spots were calculated by subtraction of the spots in the
negative controls. In order to avoid influences of assay variability,
all 4 samples (pre-, 7 d, 28 d, and 1 year) of the study participants
were measured in the same experiment employing the same batch
of IFNc coated Elispot plates.
2.3. Cytokine detection in supernatants
After 5 days of PBMC stimulation, cell culture supernatants were
collected and stored at80 C until further use. Subsequently, IFNc,
IL13, IL10, IL17, and IL21 concentrations in the supernatants were
determined by commercially available multiplex bead-based
immunoassay kits according to the manufacturer’s instructions
(Bio-Rad Laboratories). Samples with concentrations below the
lower limit of quantification were assigned half the concentration
of the lowest measurement. Cytokine concentrations in the nega-
tive controls were subtracted from those in the antigen stimulated
samples.
2.4. Detection of CD4+CXCR5+ICOS+IL21+ cells by flow cytometry
To assess the potency of circulating T-cells to produce IL21,
3 ⁄ 105 PBMCs/well of samples pre- as well as 7 and 28 days
post-vaccination were incubated with medium only (negative con-
trol) or with a cell stimulation cocktail containing phorbol 12-
myristate 13-acetate (PMA) and ionomycin (IONO) in a suboptimal
2000 dilution (eBiosciences) in triplicate. Cells were incubated
for 6 h at 37 C with 5% CO2. After one hour, GolgiPlug protein
transport inhibitor containing Brefeldin A (1000 dilution, BD)
was added to each well. After thorough washing, cells were incu-
bated for 30 min with a mixture of Life-Death Zombie Aqua fluo-
rescent dye (Biolegend) and surface antibodies in FACS buffer,
containing PBS with 0.5%BSA and 2 mM EDTA. The following anti-
bodies were used for the surface staining: CD3 (UCHT1) – V450,
CD4 (RPA-T4) – APC, CXCR5 (RF8B2) – PerCP-Cy5.5, PD1 (MIH4)
– FITC (all BD), and ICOS (C398.4A) – APC-Cy7 (Biolegend). There-
after, cells were washed with PBS, and permeabilized for 20 min
with Cytofix/Cytoperm (BD). A Perm/Wash solution (BD) was used
to wash the cells. In addition, the cells were stained for 30 min
Fig. 1. Participants flow chart.
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ing intracellular IL21 and CD4, respectively. After washing, the cells
were resuspended in cold FACS-fixation buffer (Biolegend) until
measurement. Flowcytometry analysis was performed on a 4-
lazer LSR Fortessa (BD) and data was analyzed using FlowJo V10.
2.5. Serological analysis
Tetanus and meningococcal specific IgG concentrations were
determined using the fluorescent-bead-based multiplex
immunoassay (MIA) as previously described [34,35].
2.6. Statistics
The number of TT-specific IFNc spots, cytokine concentrations,
CD4+CXCR5+ICOS+IL21+ cell responses, and the IgG responses at
the different time points were compared with the Wilcoxon signed
rank test, preceded by the Friedman test. Correlations were deter-
mined by the Spearman’s rho correlation test. Graphpad V7 and
SPSS V22.0 were used.3. Results
3.1. TT-specific IFNy-producing cells are boosted after vaccination
Numbers of TT-specific IFNc-producing T-cells were enumer-
ated pre- and post-vaccination (Fig. 2). Pre-vaccination, already
high numbers (>10 spots/105 PBMCs) of TT-specific IFNc-Fig. 2. Numbers of TT-specific IFNc producing cells. (a) The numbers of IFNc producin
stimulation with Tetanus Toxoid (TT). The horizontal line indicates the geometric mean c
vaccination. The different time points were compared with the Wilcoxon signed rank teproducing cells were found in the majority of the participants
(16 out of 22). These numbers significantly increased 28 days
post-vaccination; a strong trend was seen after 7 days. One year
post-vaccination, the numbers of TT-specific IFNc-producing cells
returned to pre-vaccination values (Fig. 2a). Although the response
was highly variable (Fig. 2b), most participants showed an
enhanced IFNc T-cell response either at day 7 or at day 28 post-
vaccination, indicating that vaccination with a TT-carrier protein
boosted a short-term Th1 type response in middle-aged adults.3.2. Vaccination with a TT-carrier protein boosted mixed T-helper
cytokine responses
Next, we analyzed TT-specific Th1 (INFc), Th2 (IL10, IL13), Th17
(IL17) and TFH (IL21) cytokine secretion profiles. Similar to the
numbers of IFNc-producing cells, TT vaccination led to increased
TT-specific IFNc production at days 7 and 28 post-vaccination
(Fig. 3a). Also, a marked increase of the IL13 production was seen
post-vaccination (Fig. 3b), which resulted in a relative decrease
of the TT-specific IFNc/IL13 ratio at 28 days post-vaccination
(Fig. 3c).
Additionally, TT-specific IL10 production was largely enhanced
7 days post-vaccination in all participants, after which this response
gradually declined 28 days post-vaccination (Fig. 3d). Moreover, a
significant but limited enhancement of TT-specific IL17 secretion
was observed both at day 7 and 28 (Fig. 3e). Of note, TT-specific
IL21 productionwas below detection limit (data not shown). Overall,
7 days post-vaccination, a mixed cytokine profile was induced ing cells/105 PBMCs pre- and post-vaccination in the negative control (BL) and after
oncentration. (b) Paired numbers of IFNc producing cells/105 PBMCs pre- and post-
st preceded by the Friedman test. **p < 0.01, n = 22.
Fig. 3. TT-specific cytokine responses. Concentrations (pg/mL) of IFNc (a), IL13 (b), IL10 (d), and IL17 (e) in cell culture supernatants after 5 days of Tetanus Toxoid
stimulation. The red line indicates the geometric mean concentration. (c) The IFNc/IL13 ratio pre- and post- vaccination. The different time points were compared with the
Wilcoxon signed rank test preceded by the Friedman test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n = 20. (f) The delta TT-specific cytokine responses at day 7 (day 7 –
day 0) per donor.
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(IFNy) or Th2 (IL10, IL13) dominated response (Fig. 3f).
3.3. The TT-carrier protein induced circulating CD4+CXCR5+ICOS+IL21
+ cells
Although we did not detect TT-specific IL21 production, we next
investigated the induction of circulating CD4+CXCR5+ICOS+IL21+cells following vaccination by TT-specific or polyclonal stimulation
with PMA/IONO (Fig. 4a). Since PMA/IONO stimulation caused the
internalization of CD4 by T-cells, both intra- and extra-cellular
staining of CD4 was performed to detect the total CD4 T-cell pool.
Firstly, no intracellular IL21 production was observed after TT-
specific stimulation (data not shown). Stimulation with PMA/IONO
induced IL21 production in both the CXCR5+ and CXCR5- subsets,
although this production was significantly higher in the CXCR5+
Fig. 4. Induction of circulating CD4+CXCR5+ICOS+IL21+ cells post-vaccination. (a) Gating strategies used for characterization of the CD4+CXCR5+ICOS+IL21+ cells. A
representative sample is shown. (b) Percentages of ICOS+ cells within the CXCR5+ and CXCR5- populations pre- and post-vaccination (7 and 28 days). (c) Percentages of IL21+
cells within the CXCR5+ and CXCR5- populations pre- and post-vaccination (7 and 28 days). (d) Percentages of ICOS+IL21+cells within the CXCR5+ and CXCR5- populations
pre- and post-vaccination (7 and 28 days). The horizontal lines in the graph represent the geometric mean percentages. The different time points were compared with the
Wilcoxon signed rank test preceded by the Friedman test. CXCR5+ and CXCR5- cells at the different time points were compared with the Mann Whitney U test. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, n = 20.
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(Fig. 4b). Similarly, higher frequencies of IL21+ICOS+ cells were
detected in the CXCR5+ subset (Fig. 4d). Seven days post vaccina-
tion a significant increase in the frequency of IL21+ICOS+ cells
within the CXCR5+ compartment was observed (Fig. 4d). This
response was variable between the participants, with 17 respon-
ders and 3 non-responders. Additionally, some samples (n = 12)
were analyzed for PD1 expression (Supplementary Fig. 1b). A
strong significant correlation between the percentages of CXCR5
+IL21+ICOS+ cells and CXCR5+IL21+ICOS+PD1+ cells 7 days post-
vaccination was found (Supplementary Fig. 1c). These results indi-
cate a significant increase in activated T-cells that have high poten-
tial for B-cell help after vaccination with a TT-carrier protein in
middle-aged adults.3.4. TT-specific T-helper cell cytokines correlate with the CD4+CXCR5
+ICOS+IL21+ cell response 7 days post-vaccination
We further assessed whether the increase in the CD4+CXCR5
+ICOS+IL21+ cells at 7 days post-vaccination correlated with TT-
specific T-helper cytokine production, both pre- and post-
vaccination. Seven days post-vaccination, a strong correlationwas observed between the increase in CD4+CXCR5+ICOS+IL21+
cells and the increase in TT-specific IL10 and IL13 production
(Table 1a, sub 1). The increase in CD4+CXCR5+ICOS+IL21+ cells
did not correlate with the TT-specific Th17 or Th1 response,
although a trend was seen for the latter.
Next we analyzed the correlation between pre-vaccination TT-
specific cytokine production and the increase in CD4+CXCR5
+ICOS+IL21+ cells at day 7. A significant correlation was found
between the production of pre-vaccination TT-specific IFNc and
the increase in CD4+CXCR5+ICOS+IL21+ cells 7 days post-
vaccination (Table 1a, sub 2). Moreover, a positive trend was found
for the other T-helper subsets, suggesting that the presence of pre-
vaccination TT-specific T-helper cells enhanced the CD4+CXCR5
+ICOS+IL21+ cells responses.3.5. TT-specific T-helper cell responses do not correlate with antigen
specific IgG responses
The TT-conjugated meningococcal vaccine induced clear anti-
body responses to TT and the meningococcal C polysaccharides
(MenC-PS) (Fig. 5). Yet, no correlations between the TT-specific
T-helper cell responses or the CD4+CXCR5+ICOS+IL21+ cells
Table 1a
Correlations between the TT-specific cytokine responses and the induction of
circulating CD4+CXCR5+ICOS+IL21+ cells.
Parameter variable Spearman’s rho p-value
1. Delta TT-specific cytokine
response at day 7
IFNc 0.650 0.058






(pg/ml) IL13 0.503 0.138
IL10 0.661 0.053
IL17 0.571 0.084
The delta % CD4+CXCR5+ICOS+IL21+ cells at days 7 (7 days – pre-vaccination) was
used in the correlations. n = 10. The Spearman’s rho correlation test was used. The
p-values of significant (p < 0.05) correlations are indicated in bold.
Table 1b
Correlations between the induced circulating CD4+CXCR5+ICOS+IL21+ cell response,
TT-specific cytokine responses and the TT and MenC-PS specific IgG responses.
T1-T0 response parameter Time point Spearman’s rho p-value
CXCR5+ICOS+IL21+ TT IgG 28 days 0.135 0.569
TT IgG 1 year 0.271 0.248
MenC IgG 28 days 0.056 0.816
MenC IgG 1 year 0.039 0.870
IL10 TT IgG 28 days 0.168 0.478
TT IgG 1 year 0.026 0.915
MenC IgG 28 days 0.194 0.413
MenC IgG 1 year 0.206 0.384
IL13 TT IgG 28 days 0.265 0.259
TT IgG 1 year 0.277 0.238
MenC IgG 28 days 0.152 0.523
MenC IgG 1 year 0.217 0.359
IFNc TT IgG 28 days 0.245 0.298
TT IgG 1 year 0.084 0.724
MenC IgG 28 days 0.314 0.177
MenC IgG 1 year 0.307 0.188
IL17 TT IgG 28 days 0.198 0.402
TT IgG 1 year 0.176 0.458
MenC IgG 28 days 0.060 0.801
MenC IgG 1 year 0.048 0.840
The delta % of CD4+CXCR5+ICOS+IL21+ cells at days 7 (7 days – pre-vaccination)
was used in the correlations, as well as the delta cytokine production (7 days – pre-
vaccination). n = 20. The Spearman’s rho correlation test was used.
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were detected, using delta (Table 1b), absolute, and fold change T-
cell responses (data not shown). On a side note, positive correla-
tions were found between the pre- and post-vaccination IgG con-
centrations for TT (7d: rho: 0.591 p = 0.006; 28 d: rho: 0.711
p = <0.0001, 1y: rho: 0.713 p < 0.0001), but not for MenC. Adjusting
for pre-vaccination immunity did not change our results. Similar
results were obtained for the other meningococcal serotypes, and
for the IgG subclass responses (data not shown).4. Discussion
Within this study, we show that vaccination of middle-aged
adults with a TT-carrier protein, used to initiate T-cell help in
response to meningococcal polysaccharides, induced a mixed
Th1, Th2, and Th17 T-cell response, although some participants
showed a clear Th1 (IFNy) or Th2 (IL10, IL13) dominated response.
In addition, the enhanced frequencies of circulating CD4+CXCR5
+ICOS+IL21+ cells 7 days post-vaccination suggests the induction
of activated T-cells with TFH cells properties by a TT-carrier protein
in older adults. These T-helper cell responses are suggestive of
effective T-cell help towards the B-cells in response to the
meningococcal polysaccharides, although we did not find a direct
correlation between the T-cell response induced by the carrier pro-
tein and the meningococcal specific antibody responses.
Although a mixed cytokine response was observed, our data
suggests a slightly skewed Th2 response post-vaccination, mainly
represented by a strong IL10 response 7 days post-vaccination
and a decreased post-vaccination IFNy/IL13 ratio. The strong IL10
response may both regulate the Th1 response [36], and stimulate
the antibody responses towards the bacterial polysaccharidesFig. 5. Anti TT and MenC-PS specific IgG responses. TT (a) and MenC-PS (b) specific IgG r
the Wilcoxon signed rank test preceded by the Friedman test. **p < 0.01, ****p < 0.0001, n[12,13]. This positive effect of IL10 was strengthened by the strong
positive correlation between the IL10 production and the circulat-
ing CD4+CXCR5+ICOS+IL21+ cell response at day 7 post-
vaccination.
Antigen specific detection of IL21 production by T-cells is noto-
riously difficult, since B-cells directly consume secreted IL21 and
the TFH-cells need vigorous in vitro stimulation to produce IL21
[31,37,38]. Therefore, we assessed the potency of IL21 production
by T-cells following PMA/IONO stimulation and intercellular detec-
tion of IL21. Indeed, IL21+ cells were found in both the CXCR5+ and
CXCR5- subset, as was also shown by others [22,23,31]. Yet, higher
frequencies of IL21+ cells were observed in the CXCR5+ subset as
compared to the CXCR5- counterpart, which is in agreement with
others [23]. Although it was previously shown that IL21 production
of both subsets provided help towards B-cells, this was signifi-
cantly increased in CXCR5+ cells due to the elevated expression
of ICOS, a B-cell co-stimulator [22]. Therefore, IL21 production
alone is perceived insufficient to determine efficient TFH-cell
responses [22,31]. Post-vaccination, we observed a tendency
towards increased expression of ICOS in the CXCR5+ subset (data
not shown), which is in line with findings by Herati et al. after
influenza vaccination in the elderly [18]. Taken together, our find-
ings of increased frequencies of CXCR5+ICOS+IL21+ cells 7 daysesponses pre-, and post- vaccination. The different time points were compared with
= 20.
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strengthened by the strong correlation between the frequencies
of CXCR5+ICOS+IL21+ cells and the CXCR5+ICOS+IL21+PD1+ cells
7 days post-vaccination, since circulating PD1+ TFH cells share
functional properties with GC TFH cells [20,23,32].
In addition, we observed a correlation between the increased
frequencies of CD4+CXCR5+ICOS+IL21+ cells at day 7 and the pres-
ence of TT-specific pre-vaccination cytokine production, indicating
that pre-vaccination T-cell immunity enhances T-cell responses
upon conjugate-carrier vaccination. Although only 3 of the partic-
ipants received a TT vaccination after the year 2000, pre-
vaccination TT-specific T-cell cytokine production was observed
in most participants, which indicates that TT-specific T-helper cells
persist for years or even decades after historical vaccinations in
most participants. However, due to the exclusion of individuals
with recent (<5 years) TT vaccinations in this study, the effects of
recent tetanus vaccinations on the T-cell response towards the
TT-carrier protein remains unknown. Of note, pre-vaccination TT-
specific IgG concentrations did not correlate with TT-specific cyto-
kine production and thus cannot be used as surrogate marker for
the presence of TT-specific T-cell immunity.
In spite of the induction of T-cell responses that favour B-cell
help by the TT-carrier protein, we did not observe an association
between the strength of the T-cell response and the TT or meningo-
coccal polysaccharide specific antibody concentrations. The
absence of this correlation might be explained by several factors.
First of all, the multivalent nature of the meningococcal vaccina-
tion might complicate the detection of a correlation between the
T-cell and the humoral response. Moreover, the different polysac-
charide antigens induced diverse antibody responses within the
same person (data not shown). Therefore, we suggest a large effect
of the existing B-cell repertoire in response to the polysaccharide
antigens, a notion corroborated by the findings of other studies
[28,39]. Additionally, the lack of a correlation between the T-
helper cell and antibody responses at the time points analysed
may be explained by potential differences in peripheral B- and T-
cell kinetics. Furthermore, we propose that simply the presence
but not the strength of the T-cell response is sufficient to induce
an effective vaccine antibody response, also that is described for
a conjugated meningococcal vaccination in infants [40]. Finally,
although our results might suggest the induction of circulating
activated T-cells with TFH cell properties after vaccination, the
exact functionality of these CD4+CXCR5+ICOS+IL21+ cells is cur-
rently unknown. In particular the relation of these CD4+CXCR5
+ICOS+IL21+ cells to a possible TFH cell response in the GCs, clearly
awaits further confirmation, especially in relation to immunologi-
cal ageing, since GC and TFH-cell functionality might be altered
with advancing age [17,41]. It has been described that circulating
TFH-cells did correlate with influenza specific antibody responses
post-vaccination in young adults but not in the elderly [18], this
might indicate that GC responses are diminished in older adults
although circulating TFH cells are present.
In this study, we did not detect clear age related differences in
the T-cell responses, which might be influenced by the limited age
range, small sample size in our study, and possible confounding
effects of pre-vaccination T-cell immunity.
In conclusion, vaccination with a TT-carrier protein in middle-
aged adults induced a mixed TT-specific T-helper cell response.
Moreover, the induction of circulating CD4+CXCR5+ICOS+IL21+
cells 7 days post-vaccination suggests a circulating T-cell response
with high potential for B-cell help. Subsequently, the characteris-
tics of these T-cells proposes effective T-cell help towards B-cells
in response to the meningococcal polysaccharides, although a
direct correlation with the antibody responses was not found, a
finding that warrants further clarification especially in the context
of immune ageing. Notwithstanding, the robust T-helper cellresponse, decades after previous TT vaccination, adds to the knowl-
edge on the immunological fitness of middle-aged adults. More-
over, these results strengthen the classification of this age group
as an interesting target group for future vaccine interventions, to
stimulate memory immunity before reaching old age.
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